Wordt geladen...
Intraperitoneal α-Emitting Radioimmunotherapy with (211)At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. After extensive preclinical work with α-particle–emitting (211)At, we performed a phase I trial with intraperitoneal α-particle therapy in epithelial ovarian cancer using (211)At conjugated to MX35, the an...
Bewaard in:
| Gepubliceerd in: | J Nucl Med |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Society of Nuclear Medicine
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681696/ https://ncbi.nlm.nih.gov/pubmed/30683761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.220384 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|